Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

Patent metadata

Field	Value
Publication number	US-12310992-B2
Application number	US-202318535745-A
Country	US
Kind code	B2
Filing date	Dec 11, 2023
Priority date	Aug 1, 2012
Publication date	May 27, 2025
Grant date	May 27, 2025

Abstract

The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

First claim

What is claimed is:

1. A method for treatment pulmonary hypertension, comprising administering to a subject suffering from pulmonary hypertension (i) a first prostacyclin and (ii) microvesicles obtained from mesenchymal stem cells (MSCs) contacted with a second prostacyclin prior to administration.

2. The method of claim 1 , wherein the first and second prostacyclin are the same prostacyclin.

3. The method of claim 1 , wherein the first or second prostacyclin is treprostinil.

4. The method of claim 1 , wherein the first prostacyclin and microvesicles are co-administered.

5. The method of claim 1 , wherein the first prostacyclin is administered before the microvesicles are administered.

6. The method of claim 1 , wherein the first prostacyclin is administered after the microvesicles are administered.

7. The method of claim 1 , wherein the microvesicles are isolated from a culture medium comprising the MSCs.

8. The method of claim 1 , further comprising administering to the subject the MSCs.

9. The method of claim 1 , further comprising administering to the subject endothelial progenitor cells (EPCs).

10. The method of claim 1 , wherein the patient is suffering from pulmonary arterial hypertension.

11. A method for treating pulmonary arterial hypertension comprising:
(a) providing isolated endothelial progenitor cells (EPCs);
(b) treating the isolated EPCs in vitro or ex vivo with a prostacyclin during expansion of the EPCs, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic activity; and
(c) administering a composition comprising the treated EPCs to a human subject suffering from pulmonary hypertension.

12. The method of claim 11 , wherein the EPCs are isolated from a human being, a tissue, or cell culture.

Assignees

• United Therapeutics Corp

Inventors

• Jeffs Roger
• Petersen Thomas
• Ilagan Roger M
• Wade Michael

Classifications

• C12N2501/999

  Small molecules not provided for elsewhere · CPC title

• C12N5/0692

  Stem cells; Progenitor cells; Precursor cells · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• A61K35/02

  from inanimate materials (carbon A61K33/44) · CPC title